12 not yet recruiting, 11 recruiting, 4 completed, 4 unknown. 9 Phase 2, 5 Not applicable, 3 Phase 1, 3 Phase 3, 2 Early Phase 1.
Follow Pancreatic Cancer Resectable: new trials by email Literature Review of Pancreatic Cancer Resectable trials Research Report on Pancreatic Cancer Resectable
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer Nogapendekin Alfa Inbakicept (N803), Sotevtamab, Zabadinostat (CXD101) - Pancreatic Cancer Resectable, Pancreatic Cancer | Phase 1 | Withdrawn | ImmunityBio, Inc. | 2026-09-01 | 2026-08-28 | |
| EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer ASP-1929 photoimmunotherapy - Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection, Pancreatic Cancer Borderline | Phase 1 / Phase 2 | Not yet recruiting | Brown University | 30 | 2026-09-01 | 2026-07-13 |
| Study on the Construction and Application of a Large Model Corpus for Pancreatic Cancer Based on Real Clinical Cases Pancreatic Cancer, Pancreatic Cancer Metastatic | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 3000 | 2026-08-01 | 2026-07-21 | |
| Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer Pancreatic Tumor, Benign, Pancreatic Cancer, Adult | Recruiting | Shanghai Zhongshan Hospital | 320 | 2026-05-11 | 2026-06-29 | |
| A Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy (NAC) for Patients With Resectable Borderline Pancreatic Adenocarcinoma (PDAC) mFOLFIRINOX (modified FOLFIRINOX) - Pancreas Adenocarcinoma (MSI-H), Pancreatic Cancer Resectable | Not applicable | Not yet recruiting | Institut Paoli-Calmettes | 367 | 2026-05-01 | 2026-05-18 |
| Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer Surufatinib, Toripalimab, mFOLFIRINOX - Pancreatic Cancer Resectable | Phase 2 | Not yet recruiting | Sun Yat-sen University | 30 | 2026-03-31 | 2026-03-13 |
| Neoadjuvant Chemotherapy for Elderly with Pancreatic Head Cancer Neoadjuvant Chemotherapy (NAT) Group - Pancreatic Cancer Resectable, Pancreatic Cancer Stage II | Not yet recruiting | Azienda Unita Sanitaria Locale di Piacenza | 240 | 2026-01-01 | 2025-03-11 | |
| Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Cancer Sample Collection - Pancreatic Cancer Resectable, Pancreatic Cancer Non-resectable | Active not recruiting | Zhejiang Cancer Hospital | 70 | 2025-12-08 | 2026-01-08 | |
| Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer mFOLFIRINOX neoadjuvant chemotherapy / Nab-paclitaxel and gemcitabine - Pancreatic Cancer Resectable | Phase 3 | Not yet recruiting | Helsinki University Central Hospital | 381 | 2025-09-01 | 2025-09-04 |
| Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer Neoadjuvant chemotherapy, Upfront Surgery Group - Pancreas Cancer, Periampullary Cancer | Phase 3 | Recruiting | Minia University | 262 | 2025-07-20 | 2026-09-11 |
| Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer Minimal Residual Disease, Pancreatic Cancer Resectable | Not yet recruiting | Shanghai Zhongshan Hospital | 66 | 2025-04-20 | 2025-04-24 | |
| Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer. individualized anti-tumor new antigen iNeo-Vac-R01 injection, Gemcitabine + Capecitabine, Sintilimab injection - Pancreatic Cancer Resectable | Phase 1 / Phase 2 | Not yet recruiting | Zhejiang University | 60 | 2025-04-01 | 2025-03-21 |
| Antecolic Versus Retrocolic Gastrojejunostomy During Whipple's Procedure Antecolic gastrojejunostomy, Retrocolic gastrojejunostomy - Pancreatic Cancer Resectable, Pancreas Neoplasms | Not applicable | Recruiting | University of Thessaly | 76 | 2025-03-30 | 2025-06-06 |
| Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery Local Anesthesia, Laparoscopic Transversus Abdominis Plane block - Oncologic Surgery, Cancer | Not applicable | Recruiting | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | 48 | 2025-02-05 | 2025-09-18 |
| Conventional Partial Pancreatoduodenectomy Versus an Extended Pancreatoduodenectomy for Pancreatic Head Cancers Expanded pancreaticoduodenectomy surgery, Pancreaticoduodenectomy - Pancreatic Cancer Resectable | Not applicable | Not yet recruiting | First Affiliated Hospital Xi'an Jiaotong University | 270 | 2024-12-01 | 2024-11-25 |
| Oncological Safety of Spleen Preservation in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID) Pancreatic Cancer Resectable, Pancreatectomy | Active not recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 94 | 2024-11-28 | 2026-07-22 | |
| Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer Nimotuzumab, AG - Pancreatic Cancer Resectable | Phase 2 | Recruiting | Zhejiang Provincial People's Hospital | 57 | 2024-11-15 | 2024-12-09 |
| Spanish Registry of Quality Indicators and Adverse Events of Endoscopic Retrograde Cholangiopancreatography Endoscopic retrograde cholangiopancreatography (ERCP) - Choledocholithiasis, Choledocholithiasis With Acute Cholangitis | Not yet recruiting | Germans Trias i Pujol Hospital | 3000 | 2024-11-01 | 2024-11-01 | |
| Early Diagnosis of Pancreatic Cancer Via Deciphering Multi-modal Immunological Signatures Pancreatic Cancer Resectable | Not yet recruiting | Zhejiang University | 3000 | 2024-08-01 | 2024-07-16 | |
| Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer Fixed neoantigen tumor vaccine, personalized neoantigen tumor vaccine, PD-1 inhibitor - Pancreatic Cancer Resectable, Chemotherapy-intolerant | Early Phase 1 | Recruiting | Ruijin Hospital | 20 | 2024-07-16 | 2025-11-17 |
Showing 20 of 36. Sign in to see all of them.
Pancreatic Neoplasms (14) · Biliary Tract Neoplasms (3) · Neoplasm, Residual (3) · Pancreatic cancer, adult (3) · Colorectal Neoplasms (2) · Gastrointestinal Neoplasms (2) · Agnosia (1) · Anxiety Disorders (1) · Biliary Fistula (1) · Cholangiocarcinoma (1) · Cholangitis, Sclerosing (1) · Choledocholithiasis (1) · Colonic Neoplasms (1) · Depression (1) · Digestive System Neoplasms (1)
Neoplasms (21) · Digestive System Diseases (19) · Neoplasms by Site (18) · Digestive System Neoplasms (17) · Endocrine Gland Neoplasms (14) · Endocrine System Diseases (14) · Pancreatic Diseases (14) · Pathological Conditions, Signs and Symptoms (10) · Pathologic Processes (8) · Biliary Tract Diseases (4) · Neoplastic Processes (4) · Colonic Diseases (3) · Gastrointestinal Diseases (3) · Intestinal Diseases (3) · Intestinal Neoplasms (3)
Gemcitabine (5) · 130-nm albumin-bound paclitaxel (2) · Fluorouracil (2) · Irinotecan (2) · Leucovorin (2) · Neoadjuvant Therapy (2) · Oxaliplatin (2) · Taxes (2) · ALT-803 (1) · Anesthesia, Local (1) · Antineoplastic Agents (1) · Aspirin (1) · Blood Specimen Collection (1) · Capecitabine (1) · Cholangiopancreatography, Endoscopic Retrograde (1)
BAIYONG SHEN (2) · Shanghai Zhongshan Hospital (2) · University of Thessaly (2) · Zhejiang University (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) (1) · Ankara Etlik City Hospital (1) · Azienda Unita Sanitaria Locale di Piacenza (1) · Beijing Immunochina Medical Science & Technology Co., Ltd. (1) · Brown University (1) · City of Hope Medical Center (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · German Cancer Research Center (1) · Germans Trias i Pujol Hospital (1) · Helsinki University Central Hospital (1)
China (14) · United States (5) · Greece (3) · Spain (3) · Japan (2) · South Korea (2) · Egypt (1) · Finland (1) · France (1) · Italy (1) · Netherlands (1) · Norway (1) · Sweden (1) · Turkey (Türkiye) (1)
Ajay Goel, PhD (1) · Alexandros Diamantis, MD, MSc, PhD (1) · Ashwin Somasundaram, MD (1) · Baiyong Shen, M.D&Ph.D (1) · Baiyong Shen, Ph.D (1) · Casey Allen, MD (1) · Dimitrios Symeonidis (1) · Edgar Castillo-Regalado, MD (1) · Elena Orlandi, MD (1) · Galip Can Uyar, MD (1)
PMID 28143873, PMID 29852194, PMID 29961772, PMID 34132691, PMID 34748675, PMID 35850192, PMID 36170373, PMID 37026827, PMID 37069476, PMID 37121331, PMID 38740994, PMID 38772364, PMID 38838643, PMID 39920992, PMID 40038255, PMID 40686333, PMID 40841473, PMID 42241671, PMID 42749887
R01CA181450 (1)